Product Description
Pfizer is developing PF-07275315, an anti-IL-4/ IL-13/ TSLP biologic for the development of Atopic Dermatitis. (Sourced from: https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_31JAN2023.pdf?Y9dll8b2GbzLJ_q0NsCadkr_zh15l3or)
Mechanisms of Action: IL4 Inhibitor, IL13 Inhibitor, TSLP Inhibitor
Novel Mechanism: No
Modality: Trispecific Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Hungary, India, Italy, Japan, Poland, Puerto Rico, South Africa, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 19
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Pfizer announced they will present P2 Dermatitis, Atopic results in 4Q26 for Tilrekimig
- Clinical Outcomes Reported - Pfizer presented P2 Dermatitis, Atopic results on 2026-10-01 for Tilrekimig
- Clinical Outcomes Reported - Pfizer presented P2 Dermatitis, Atopic results on 2026-03-09 for Tilrekimig
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Dermatitis, Atopic|Skin Diseases, Eczematous|Skin Diseases, Genetic
Phase 2: Airway Obstruction|Dyspnea|Respiratory Sounds
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07765888 |
C4531007 | P3 |
Recruiting |
Skin Diseases, Genetic|Dermatitis, Atopic|Skin Diseases, Eczematous |
2028-03-10 |
92% |
2026-11-13 |
|
NCT05995964 |
C4531002 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2026-11-12 |
49% |
2026-10-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06977581 |
C4531029 | P2 |
Recruiting |
Respiratory Sounds|Airway Obstruction|Dyspnea|Asthma |
2027-03-08 |
31% |
2026-05-05 |
Primary Endpoints|Treatments |
NCT07363694 |
COPD | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2030-10-24 |
88% |
2026-10-23 |
Primary Endpoints |
jRCT2031250163 |
jRCT2031250163 | P2 |
Recruiting |
Asthma |
2027-07-26 |
|||
2024-517866-40-00 |
C4531029 | P2 |
Not yet recruiting |
Asthma |
2027-07-26 |
31% |
||
jRCT2051240044 |
jRCT2051240044 | P2 |
Not yet recruiting |
Dermatitis, Atopic |
2026-02-13 |
|||
CTR20242718 |
CTR20242718 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
None |
2026-09-27 |
Patient Enrollment|Treatments|Trial Status |
|
NCT07839884 |
C4531015 | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2034-05-12 |
65% |
2026-09-25 |
|
jRCT2061250099 |
jRCT2061250099 | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2031-01-16 |
|||
NCT07869043 |
C4531009 | P3 |
Recruiting |
Asthma |
2029-06-07 |
72% |
2026-11-06 |
|
jRCT2031260599 |
jRCT2031260599 | P3 |
Not yet recruiting |
Dermatitis, Atopic |
2029-06-05 |
|||
jRCT2041260169 |
jRCT2041260169 | P3 |
Not yet recruiting |
Dermatitis, Atopic |
2029-06-05 |
|||
NCT07772921 |
C4531037 | P3 |
Recruiting |
Asthma |
2029-06-01 |
88% |
2026-10-07 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT07792941 |
C4531039 | P1 |
Active, not recruiting |
Healthy Volunteers |
2027-02-20 |
49% |
2026-10-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07783425 |
Tilrek | P3 |
Recruiting |
Skin Diseases, Eczematous|Dermatitis, Atopic|Skin Diseases, Genetic |
2028-09-08 |
90% |
2026-11-07 |
|
NCT06675188 |
C4531004 | P1 |
Completed |
Healthy Volunteers |
2025-07-14 |
38% |
2025-08-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05411588 |
C4531001 | P1 |
Completed |
Healthy Volunteers |
2024-05-13 |
48% |
2024-06-04 |
Primary Completion Date|Primary Endpoints |
2024-518587-12-00 |
C4531031 | P2 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2031-01-29 |
88% |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/09/2026 |
News Article |
Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis |